Hypertrophic cardiomyopathy (HCM) is extremely heterogeneous with regard to both genetic origins and phenotypic expressions.1,2 The age of onset of the disease has been recently identified as a major determinant of prognosis, phenotype, and association with syndromic features. This has led to the recognition of pediatric HCM as a specific disease entity1 requiring specific management. Left ventricular outflow tract (LVOT) obstruction is a defining feature,3 which when severe requires surgical myectomy usually through a transaortic approach.
